-
2023-503481-23-00
5
2023-03-20
Maintenance treatment in metastatic non-squamous lung cancer
-
2024-511866-36-00
5
2023-03-11
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae se
-
2024-514913-37-00
11
2023-01-12
Respiratory distress
-
2024-514328-18-00
7
2022-12-06
Spinocerebellar ataxia types 1, 3 and Huntington's disease
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2024-512382-13-00
5
2022-10-04
Migraine (with or without aura)
-
2024-511899-32-00
10
2022-08-31
Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
-
2024-513671-40-00
5
2022-06-29
HPV vaccine
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-513191-17-00
4
2022-02-03
autoimmune hemolytic anemia
-
2024-513983-24-00
6
2021-10-29
Diabetic Macular Oedema
-
2024-513427-17-00
6
2021-05-20
Well controlled severe allergic asthma
-
2023-505924-71-00
4
2021-05-12
Adult patients with metastatic and/or unresectable Non-Small Cell Lung
-
2023-505483-11-00
6
2021-05-02
Brain abscess
-
2024-516461-36-00
5
2021-01-27
Pregnancy associated hypertension, Pre-Eclampsia, Fetal growth restric
-
2024-516409-22-00
5
2021-01-07
Type 2 Diabetes complete remission after bariatric surgery under antid
-
2024-511904-18-00
10
2020-07-08
Pancreatic adenocarcinoma (PAC)
-
2024-515276-12-00
5
2020-07-01
Postpartum Hemorrhage
-
2024-512173-27-00
5
2019-03-21
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment wi
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
-
2025-521302-17-00
10
2026-05-26
Hihg risk of cholangiocarcinoma intra hépatic resectable